文献速递血脂与心血管预防冠心病

FOURIER试验:炎症与胆固醇风险对evolocumab疗效的影响

Inflammatory and Cholesterol Risk in the FOURIER Trial.
PubMed 文献 · Circulation · 2018-03-12

FOURIER试验纳入27 564例稳定动脉粥样硬化性心血管疾病且他汀治疗下LDL-C≥70 mg/dL的患者,随机接受evolocumab或安慰剂,中位随访2.2年。结果显示,evolocumab在不同基线hsCRP分层中的相对风险降低一致,但高hsCRP患者绝对风险降低幅度更大;LDL-C与hsCRP均独立与主要终点相关。

要点

  • evolocumab降低心血管事件的相对风险在各基线hsCRP分层中一致。
  • 基线hsCRP越高,evolocumab的绝对风险降低幅度越大。
  • LDL-C与hsCRP均独立预测心血管风险,双低者事件率最低。

核心结论

  • evolocumab降低LDL-C所带来心血管事件减少在各hsCRP分层中一致,高基线hsCRP者绝对风险降低更大。
  • hsCRP与LDL-C均独立与主要终点相关,两者均低时事件率最低。

研究设计与样本

  • FOURIER试验为随机双盲安慰剂对照研究,纳入27 564例稳定动脉粥样硬化性心血管疾病且他汀治疗下LDL-C≥70 mg/dL的患者。
  • 患者随机接受evolocumab或安慰剂,中位随访2.2年(1.8-2.5)。

主要发现

  • 基线hsCRP<1 mg/L者7981例(29%),1-3 mg/L者11 177例(41%),>3 mg/L者8337例(30%)。
  • 基线hsCRP中位数1.8 mg/L(IQR 0.9-3.6),evolocumab治疗48周后变化为-0.2 mg/dL(-1.0至0.4),两组相似。
  • 安慰剂组3年主要终点Kaplan-Meier率在hsCRP<1、1-3、>3 mg/L分层分别为12.0%、13.7%、18.1%(P趋势<0.0001)。
  • 安慰剂组3年关键次要终点率对应分层分别为7.4%、9.1%、13.2%(P趋势<0.0001)。
  • evolocumab主要终点和关键次要终点的相对风险降低在各hsCRP分层一致(交互P>0.15)。

关键数值与推荐

  • 主要终点绝对风险降低在hsCRP<1、1-3、>3 mg/L分层分别为1.6%、1.8%、2.6%。
  • 关键次要终点绝对风险降低对应分层分别为0.8%、2.0%、3.0%。
  • 校正分析中LDL-C与hsCRP均独立与主要终点相关(各自P<0.0001)。

临床怎么用

  • 对稳定动脉粥样硬化性心血管疾病患者,无论基线hsCRP水平,evolocumab均可一致降低相对风险。
  • 高基线hsCRP患者使用evolocumab可能获得更大的绝对风险降低。
  • 评估残余炎症风险(hsCRP)与残余胆固醇风险(LDL-C)有助于识别高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. It is not known whether the efficacy of evolocumab is modified by baseline inflammatory risk. We explored the efficacy of evolocumab stratified by baseline high-sensitivity C-reactive protein (hsCRP). We also assessed the importance of inflammatory and residual cholesterol risk across the range of on-treatment LDL-C concentrations. METHODS: Patients (n=27 564) with stable atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL on a statin were randomly assigned to evolocumab versus placebo and followed for a median of 2.2 years (1.8-2.5). The effects of evolocumab on the primary end point of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina or coronary revascularization, and the key secondary end point of cardiovascular death, myocardial infarction, or stroke were compared across strata of baseline hsCRP (<1, 1-3, and >3 mg/dL). Outcomes were also assessed across values for baseline hsCRP and 1-month LDL-C in the entire trial population. Multivariable models adjusted for variables associated with hsCRP and 1-month LDL-C were evaluated. RESULTS: A total of 7981 (29%) patients had a baseline hsCRP<1 mg/L, 11 177 (41%) had a hsCRP 1 to 3 mg/L, and 8337 (30%) had a hsCRP >3 mg/L. Median (interquartile range) baseline hsCRP was 1.8 (0.9-3.6) mg/L and levels were not altered by evolocumab (change at 48 weeks of -0.2 mg/dL [-1.0 to 0.4] in both treatment arms). In the placebo arm, patients in higher baseline hsCRP categories experienced significantly higher 3-year Kaplan-Meier rates of the primary and key secondary end points: 12.0%, 13.7%, and 18.1% for the primary end point (Ptrend<0.0001) and 7.4%, 9.1%, and 13.2% for the key secondary end point (Ptrend<0.0001) for categories of <1, 1 to 3, and >3 mg/dL, respectively. The relative risk reductions for the primary end point and key secondary end point with evolocumab were consistent across hsCRP strata (P-interactions>0.15 for both). In contrast, the absolute risk reductions with evolocumab tended to be greater in patients with higher hsCRP: 1.6%, 1.8%, and 2.6% and 0.8%, 2.0%, and 3.0%, respectively, for the primary and key secondary end points across hsCRP strata. In adjusted analyses of the association between LDL-C and hsCRP levels and cardiovascular risk, both LDL-C and hsCRP were independently associated with the primary outcome (P<0.0001 for each). CONCLUSIONS: LDL-C reduction with evolocumab reduces cardiovascular events across hsCRP strata with greater absolute risk reductions in patients with higher-baseline hsCRP. Event rates were lowest in patients with the lowest hsCRP and LDL-C. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01764633.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018. PMID: 29530884. doi:10.1161/CIRCULATIONAHA.118.034032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。